Mark Nuijten

Mark Nuijten

Mark Nuijten

Director - A2M

Mark is medical doctor, health economist,  valuation economist,  and market access&pricing consultant. Mark has become a leading health policy and economics expert over the last two decades, reflected in more than 200 publications and leading positions in scientific societies and editorial boards. Mark was Board Director of ISPOR (2002-2004) and Chair of the Management Board of Value in Health (2002-2004). He was member of the Editorial Advisory Board of Value in Health. He obtained his PhD in health economics (2003) on the thesis “In search for more confidence in health economic modelling” at the Erasmus University, Rotterdam.

 

He is academic supervisor of PhD programs at the University of Maastricht (nutrition-economics in malnutrition, economics of obesity) and recently the University of Groningen (reimbursement policies for medical innovation, stratified medicine) in The Netherlands and he is founder of the ISPOR Special Interest Group on nutrition-economics. From 2017 he has been Adjunct Professor at ITU (Istanbul Technical University) in Turkey and in 2019/2020 he was Visiting Professor at universities in Israel.

 

He is a pioneer in the field of healthcare innovation in biotechnology and nutrition, and has been the first classical health economist successfully applying and developing Discounted Cash Flow methodologies for valuation of biotechnology innovation. For example, a Pricing Model to asses prices of expensive orphan drugs from an investor’s perspective (e.g. published in a Nature journal). Other innovative concepts are the development of a Pricing Matrix Model for research in early phase development and a Financial Valuation Algorithm for the assessment of the future positioning of a new, innovative medicinal product. His models successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, NICE in England, SMC in Scotland, TLV in Sweden, and Zin in The Netherlands).

 

Mark is founder of A2M (Ars Accessus Medica) and founding partner of the Minerva International Health Economic Network. Mark was trained as a physician and worked in clinical research before obtaining his international M.B.A. from Erasmus University, Rotterdam, where he later was senior staff member. Prior to setting up Ars Accessus Medica, Mark was a partner with MEDTAP International. As a VP Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for MEDTAP. Before his MEDTAP period, Mark was Managing Director of the IQVIA Quintiles office in the Netherlands, which included European responsibility for the policy and health economic division.

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners